Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer

Acta Oncologica

Volumn 54, Issue 3, 2015, Pages 340-348

  Stene, Guro B ^a,b,c   Helbostad, Jorunn L ^b,c   Amundsen, Tore ^b,c   Sørhaug, Sveinung ^a,b   Hjelde, Harald ^b   Kaasa, Stein ^a,b   Grønberg, Bjørn H ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CARBOPLATIN; GEMCITABINE; NAVELBINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; VINBLASTINE; VINORELBINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTHROPOMETRIC PARAMETERS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; IMAGE ANALYSIS; LOSS OF APPETITE; LUMBAR VERTEBRA; LUNG EMBOLISM; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MUSCLE MASS; MUSCULOSKELETAL SYSTEM PARAMETERS; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; QUALITY OF LIFE; SARCOPENIA; SKELETAL MUSCLE; SKELETAL MUSCLE CROSS SECTIONAL AREA; THROMBOCYTOPENIA; TREATMENT RESPONSE; AGED, 80 AND OVER; ANALOGS AND DERIVATIVES; CACHEXIA; CARCINOMA, NON-SMALL-CELL LUNG; COMPLICATION; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; HUMANS; LUMBOSACRAL REGION; LUNG NEOPLASMS; MORTALITY; MUSCLE, SKELETAL; PALLIATIVE CARE; PATHOLOGY; PILOT PROJECTS; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SEX FACTORS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CACHEXIA; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; LUMBOSACRAL REGION; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PALLIATIVE CARE; PILOT PROJECTS; SARCOPENIA; SEX FACTORS; VINBLASTINE;

EID: 84924241206     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.953259     Document Type: Article

References (27)

1. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: Facts and numbers. J Cachexia Sarcopenia Muscle 2010;1:1-5.
2. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: A new definition. Clin Nutr 2008;27:793-9.
3. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011;12:489-95.
4. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non-small cell lung cancer: A contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 2010;91:1133S-7S.
5. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31:1539-47.
6. Parsons HA, Baracos VE, Dhillon N, Hong DS, Kurzrock R. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One 2012;7:e29330.
7. Prado CM, Sawyer MB, Ghosh S, Lieffers JR, Esfandiari N, Antoun S, et al. Central tenet of cancer cachexia therapy: Do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr [Internet]. [cited 2013 Aug 21]. Available from: http://ajcn.nutrition.org/content/98/4/1012.full.pdf.
8. Antoun S, Borget I, Lanoy E. Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr Opin Support Palliat Care 2013;7:383-9.
9. Baracos V, Caserotti P, Earthman CP, Fields D, Gallagher D, Hall KD, et al. Advances in the science and application of body composition measurement. J Parenter Enteral Nutr 2012;36:96-107.
10. Murphy RA, Mourtzakis M, Chu QS, Reiman T, Mazurak VC. Skeletal muscle depletion is associated with reduced plasma (n-3) fatty acids in non-small cell lung cancer patients. J Nutr 2010;140:1602-6.
11. Dalal S, Hui D, Bidaut L, Lem K, Del Fabbro E, Crane C, et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: A pilot study. J Pain Symptom Manage 2012;44:181-91.
12. Di Sebastiano KM, Yang L, Zbuk K, Wong RK, Chow T, Koff D, et al. Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: The relationship with diabetes and anaemia. Br J Nutr 2013;109:302-12.
13. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009;15:6973-9.
14. Lieffers JR, Mourtzakis M, Hall KD, McCargar LJ, Prado CM, Baracos VE. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: Contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr 2009;89:1173-9.
15. Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R. The systemic infl ammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002;87:264-7.
16. Mannion E, Gilmartin JJ, Donnellan P, Keane M, Waldron D. Effect of chemotherapy on quality of life in patients with non-small cell lung cancer. Support Care Cancer 2014;22:1417-28.
17. Gronberg BH, Sørhaug S, Hjelde HH, Stene GB, Amundsen T, editor. Variation in health-related quality of life (HRQoL) during chemotherapy for advanced nonsmall cell lung cancer. 2013 ASCO Annual Meeting; 2013; Chicago, Illinois, USA. J Clin Oncol 2013;31(Suppl; abstr 9562).
18. Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 2009;3:269-75.
19. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008;33:997-1006.
20. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image. J Appl Physiol 2004;97:2333-8.
21. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol 2008;9:629-35.
22. Sobin LHG, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours, 7th ed. Wiley-Blackwell; Oxford. 2009.
23. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
24. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
25. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
26. Gronberg BH, Sundstrom S, Kaasa S, Bremnes RM, Flotten O, Amundsen T, et al. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer 2010;46:2225-34.
27. Scagliotti GV, DeMarinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-91.